Changes in plasma tissue factor pathway inhibitor levels during the clinical course of disseminated intravascular coagulation

Blood Coagulation and Fibrinolysis

Volumn 9, Issue 6, 1998, Pages 491-497

  Yamamuro, M ^a   Wada, H ^a   Kumeda, K ^b   Inoue, A ^a   Tsuji, I ^b   Nakasaki, T ^a   Shimura, M ^a   Hiyoyama, K ^a   Gabazza, E C ^a   Nishikawa, M ^a   Deguchi, K ^a   Shiku, H ^a   Kato, H ^c  

^a MIE UNIVERSITY   (Japan)

^b Chemo Sero Therapeutic Research Institute   (Japan)

^c NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

DIC; Free TFPI; Pre DIC; TFPI; Tissue factor

Indexed keywords

TISSUE FACTOR PATHWAY INHIBITOR;

ACUTE HEART INFARCTION; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISSEMINATED INTRAVASCULAR CLOTTING; HEMOSTASIS; HUMAN; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; PROTHROMBIN TIME; SEPSIS; THROMBOSIS;

EID: 15444353987     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199809000-00006     Document Type: Article

References (32)

1. Rapaport SI. Inhibition of factor VIIa/tissue factor-induced blood coagulation: with particular emphasis upon a factor Xa-dependent inhibitory mechanism. Blood 1989; 73: 359-365.
2. Broze GJ Jr. The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin Hematol 1992; 29: 159-169.
3. Schneider CL. The active principle of placental toxin: thromboplastin; its inactivator in blood: antithromboplastin. Am J Physiol 1947; 149: 123-129.
4. Thomas L. Studies on the intravascular thromboplastin effect of tissue suspensions in mice. II. A factor in normal rabbit serum which inhibits the thromboplastin effect of the sedimentable tissue component. Bull Johns Hopkins Hosp 1947; 81: 26-42.
5. Wun T-C, Kretzmer KK, Girard TJ, Miletich JP, Broze GJ Jr. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 1998; 263: 6001-6004.
6. Broze GJ Jr, Girard TJ, Novotny WF. The lipoprotein-associated coagulation inhibitor. In: Coller BS (editor): Progress in haemostasis and thrombosis. Philadelphia, PA: WB Saunders; 1990. pp. 243-268.
7. Rapaport SI. The extrinsic pathway inhibitor; a regulator of tissue factor-dependent blood coagulation. Thromb Haemost 1991; 66: 6-15.
8. Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ Jr. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991; 78: 387-393.
9. Lindahl AK, Jacobsen PB, Sandset PM, Abildgaard U. Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients. Blood Coag Fibrinol 1991; 2: 713-721.
10. Brandzaeg P, Sandset PM, Joo GB, Obstebo R, Abildgaard U, Kierulf P. The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningococcal disease. Thromb Res 1989; 55: 459-470.
11. Kobayashi M, Wada H, Wakita Y, Shimura M, Nakase T, Hiyoyama K, et al. Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 1995; 73: 10-14.
12. Valentin S, Nordfang O, Bregengard C, Wildgoose P. Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins. Blood Coag Fibrinol 1993; 4: 713-720.
13. Bick RL. Disseminated intravascular coagulation and related syndromes: a clinical review. Semin Thromb Hemost 1998; 14: 299-338.
14. Müller-Berghaus G. Pathophysiologic and biochemical events in disseminated intravascular coagulation: dysregulation of procoagulant and anticoagulant pathways. Semin Thromb Hemost 1989; 15: 58-87.
15. Wada H, Wakita Y, Nakase T, Shimura M, Hiyoyama K, Nagaya S, et al. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Thromb Haemost 1995; 74: 848-852.
16. Kobayashi N, Maegawa K, Takada M, Tanaka H, Gonmori H. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. Bibl Haematol 1987; 49: 265-275.
17. Wada H, Minamikawa K, Wakita Y, Nakase T, Kaneko T, Ohiwa M, et al. Hemostatic study before onset of disseminated intravascular coagulation. Am J Hematol 1994; 43: 265-275.
18. Ohno H, Kosaki G, Kambayashi J, Imaoka S, Hirata F. FOY [ethyl p-(6-guanidinohexanoxyloxy) benzoate] methanesulfonate as a serine protease inhibitor. I. Inhibition of thrombin and factor Xa in vitro. Thromb Res 1980; 19: 579-588.
19. Ohno H, Kambayashi J, Chang SW, Kosaki G. FOY [ethyl p-(6-guanidinohexanoxyloxy) benzoate] methanesulfonate as a serine protease inhibitor. In vivo effect on coagulofibrinolytic system in comparison with heparin or aprotinin. Thromb Res 1981; 24: 445-452.
20. Wada H, Mori Y, Shimura M, Hiyoyama K, Ioka M, Nakasaki T, et al. Poor outcome of disseminated intravascular coagulation or thrombocytopenic purpura patients with severe vascular endothelial cell injuries. Am J Hematol 1995; 58: 189-194.
21. Abumiya T, Enjyoji K, Kokawa T, Kamikubo Y, Kato H. An anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third Kunitz domain (K3) of free-form TFPI but not lipoprotein-associated forms in plasma. J Biochem 1995; 118: 178-182.
22. Kokawa T, Enjyoji K, Kumeda K, Kamikubo Y, Harada-shiba M, Koh H, et al. Measurement of the free form of TFPI antigen in hyperlipidemia: relationship between free and endothelial cell-associated forms of TFPI. Arterioscler Thromb Vasc Biol 1996; 16: 802-808.
23. Kamei S, Kamikubo Y, Hamuro T, Fujimoto H, Ishihara M, Yonemura H, et al. Amino acid sequence and inhibitory activity of rhesus monkey tissue factor pathway inhibitor (TFPI): comparison with human TFPI. J Biochem 1994; 115: 708-714.
24. Takahashi H, Sato N, Shibata A. Plasma tissue factor pathway inhibitor in disseminated intravascular coagulation: comparison of its behavior with plasma tissue factor. Thromb Res 1995; 80: 339-348.
25. Shimura M, Wada H, Wakita Y, Nakase T, Hiyoyama K, Nagaya S, et al. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am J Hematol 1996; 52: 165-170.
26. Kamikura Y, Wada H, Yamada A, Shimura M, Hiyoyama K, Shiku H, et al. Increased tissue factor pathway inhibitor in patients with acute myocardial infarction. Am J Hematol 1997; 55: 183-187.
27. Wada H, Minamikawa K, Wakita Y, Nakase T, Kaneko T, Ohiwa M, et al. Increased vascular endothelial cell markers in patients with disseminated intravascular coagulation. Am J Hematol 1993; 44: 85-88.
28. Wada H, Kaneko T, Ohiwa M, Tanigawa M, Hayashi T, Tamaki S, et al. Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura. Am J Hematol 1993; 44: 101-105.
29. Hoppensteadt DA, Walenga JM, Fasanella A, Jeske W, Fareed J. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. Thromb Res 1995; 77: 175-185.
30. Wesselschmidt R, Likert K, Girard T, Wun T-C, Broze GJ Jr. Tissue factor inhibitor: the carboxyterminus is required for optimal inhibition of factor Xa. Blood 1992; 79: 2004-2010.
31. Wesselschmidt R, Likert K, Huang Z, MacPhail L, Broze GJ Jr. Structural requirements for tissue factor pathway inhibitor interactions with Factor Xa and heparin. Blood Coag Fibrinol 1993; 4: 661-669.
32. Kokawa T, Abumiya T, Kimura T, Harada-Siba M, Koh H, Tsushima M, et al. Tissue factor pathway inhibitor activity in human plasma. Measurement of lipoprotein-associated and free forms in hyperlipide-mia. Arterioscler Thromb Vascular Biol 1995; 15: 504-510.